Singapore, March 16, 2010: Hard to Treat Diseases (HTDS) announced that the Chilean government approved two of its penem injectables. Following 18 months of testing and negotiations, Chilean ISP (Ministry of Health) approved two of HTDS' penem injectables, Meropenem for Injection (MEINEN) and Imipenem for Injection (IMINEN).

 

HTDS received the registration certificate for these two medications from the Chilean ISP and the company prepares to ship its products to this emerging South American market. Meropenem and Imipenem are antibiotics with wide range of efficiency, treating infections in lungs, heart, blood, bone, stomach, etc., and offer great market value for the producers and distributors.

 

Mr Terry Yuan, CEO, HTDS said, "We are happy that we finalized the test stage for these two products and received the ISP's certificate. The certificate will strengthen our supply capacity for the market. HTDS - Mellow Hope through our Chilean agent holds a powerful position on the local injectables market. Aligning these two facts, we believe that these two antibiotics will succeed in Chile and bring solid sales numbers to HTDS. Overall, penem injectables have great market potential globally, and we continue to seek new market and distribution opportunities around the world."